Harmony Biosciences Holdings, Inc.

HRMY · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders11.6%

Institutions99.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$868.45M	$714.73M	$582.02M	$437.86M	$305.44M	$159.74M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$198.34M	$156.81M	$121.24M	$83.48M	$55.52M	$27.74M
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	$670.11M	$557.92M	$460.79M	$354.37M	$249.92M	$132.00M
Gross profit as a percentage of revenue.	77.2%	78.1%	79.2%	80.9%	81.8%	82.6%
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$208.47M	$190.83M	$192.03M	$120.19M	$87.53M	$16.99M
Operating income as a percentage of revenue.	24.0%	26.7%	33.0%	27.4%	28.7%	10.6%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$158.69M	$145.49M	$128.85M	$181.47M	$34.60M	-$36.94M
Net income divided by the number of shares outstanding — profit attributable to each share.	$2.76	$2.56	$2.17	$3.07	$0.60	$-2.48
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$2.71	$2.51	$2.13	$2.97	$0.58	$-2.48

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$752.50M	$453.00M	$311.66M	$243.78M	$234.31M	$228.63M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.27B	$999.20M	$811.45M	$673.87M	$433.44M	$427.07M
All of the company's interest-bearing borrowings, short and long term combined.	$163.66M	$179.27M	$193.57M	$191.65M	$191.98M	$194.25M
Everything the company owes — debt, unpaid bills, and other obligations.	$401.41M	$340.05M	$344.46M	$271.03M	$246.94M	$329.89M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$870.22M	$659.15M	$466.99M	$402.84M	$186.51M	$97.18M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$348.20M	$219.82M	$219.39M	$144.47M	$98.56M	-$2.98M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$310000	$1.15M	$312000	$172000	$298000	$2000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$347.89M	$218.67M	$219.07M	$144.29M	$98.26M	-$2.99M

	You	Peer avg
P/E	13.7	–
Revenue Growth	+30.3%	+53.4%
ROE	20.5%	-124.2%

Harmony Biosciences Holdings, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison